You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Genetic Assay for Inhibitors of RNA-Protein Interactions

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): RNA-protein interactions play critical roles in cellular regulatory processes and in the life cycles of many pathogenic viruses, including HIV, hepatitis C, and West Nile virus, and thus represent attractive targets for therapeutics. Much of our previous work has centered on identifying and characterizing the components of key interactions and developing cell-b ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Smart Membranes for Biomolecular Detection

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this project is to develop membranes with surfaces tailored for specific affinity for a particular protein or nucleic acid molecule. These 'smart' membranes will be used in the next generation of high throughput Layered Expression Scanning (LES) applications, such as tissue screening and analytical blotting (northern and western). The hear ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. HT-production of Abs using Interaction Trap in Yeast

    SBC: AFFOMIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Affomix would like to commercialize antibody chips to enable researchers to study the human proteome. Currently, researchers use gene chips as a surrogate means to estimate the concentration of the vast variety of pro teins in cells and tissues. But given the choice, most researchers would prefer to study the proteins directly because of the; i) poor correla ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. N/A

    SBC: Alliance Pharmaceutical Corp.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  5. COMPUTER-AIDED TOOL FOR DIAGNOSTIC BREAST ULTRASOUND

    SBC: ALMEN LABORATORIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Almen Laboratories has developed a sophisticated software system for imaging applications that provides extensive tools to identify objects and image features of interest, analyze the information content and then store, retrieve and compare different objects and images of interest based on this information. This proposal adapts the technology to the problem ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Production of High Specific Activity Lutetium-177

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A separation method will be tested and evaluated to determine the feasibility of providing no carrier added lutetium-177 (Lu-177) for use in radiotherapeutic applications. An indirect method will be used to produce Lu-177 (neutron capture followed by decay). Separation of the Lu-177 from the target material will enable us to provide carrier-free Lu-177 suita ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. TITLE OMITTED

    SBC: APOLLO LIGHT SYSTEMS, INC.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  8. Amino acid derived urea based chemicals as sEH inhibitor

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat both hypertension and vascular inflammation. We demonstrated that in vivo inhibition of soluble epoxide hydrolase resulted in higher levels of EETs and in reduction of blood pressure and inflammation in animal models. Because the ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Novel epoxide hydrolase inhibitor for stroke prevention

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): A major cause of morbidity and mortality is the progression of organ damage associated with cardiovascular diseases. For instance, the incidence of stroke and costs associated with stroke damage continues to have a devastating impact on public health despite numerous treatments aimed at cardiovascular risk factors. Recent findings indicate that increasing lev ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Novel lipid-based therapies for cystic fibrosis

    SBC: AVRION MOLECULAR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Although the genetic cause of cystic fibrosis (CF), a lethal autosomal disorder, has been known for over a decade, an effective therapeutic method is still lacking. Pulmonary disease remains the major cause of morbidity and mortality in CF. The CF lung is marked by dysregulated inflammation and chronic infection, the end result being progressive bronchiectatic ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government